1849 Bio

Executive Summary

1849 Bio is a synthetic biology company that engineers custom microbes to bioleach copper from low-grade ores, offering mining operators a plug-and-play solution integrated into existing leaching circuits. Founded in 2020, the company's platform combines ore-sample sequencing, high-throughput strain engineering, and rapid validation to achieve up to 60% copper recovery—significantly higher than conventional bioleaching methods. This technology targets the untapped value in billions of dollars of stockpiled copper ore worldwide, addressing a critical need as high-grade deposits deplete and demand for copper grows. By enabling economic extraction from previously uneconomical ores, 1849 Bio positions itself as a key player in sustainable mining, reducing the environmental footprint compared to traditional smelting and acid leaching.

Upcoming Catalysts (preview)

• Q1 2027First commercial deployment with a major copper miner40% success
• Q3 2026Series B funding round to scale strain engineering and pilot operations60% success
• Q4 2026Publication of peer-reviewed field trial results demonstrating ≥60% recovery50% success